CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP) Healthcare & Pipeline Overview

CRISPR Therapeutics AG is a leading gene editing company leveraging its CRISPR/Cas9 platform to develop innovative therapies for hemoglobinopathies, oncology, regenerative medicine, and rare diseases. With a focus on ex vivo and in vivo gene-editing programs, CRISPR Therapeutics aims to revolutionize the treatment of serious diseases with high unmet medical needs.

What Is the Investment Thesis for CRSP?

CRISPR Therapeutics AG presents a notable research candidate due to its leading position in the rapidly evolving gene editing field. The company's CRISPR/Cas9 platform holds immense potential for developing curative therapies for a wide range of diseases. The anticipated commercialization of CTX001, its lead product candidate for beta-thalassemia and sickle cell disease, represents a significant near-term value driver. Positive clinical trial results and regulatory approvals could lead to substantial revenue generation. Furthermore, CRISPR Therapeutics' pipeline of allogeneic CAR-T cell therapies and in vivo gene-editing programs offers long-term growth potential. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from other gene editing companies. With a market cap of $5.96B, CRISPR Therapeutics' valuation reflects the high potential and inherent risks of its innovative technology.

Based on FMP financials and quantitative analysis

CRSP Key Highlights

• CRISPR Therapeutics' lead product candidate, CTX001, has demonstrated promising clinical results in patients with transfusion-dependent beta-thalassemia and severe sickle cell disease.
• The company has established strategic partnerships with leading healthcare companies, including Vertex Pharmaceuticals, to accelerate the development and commercialization of its gene-editing therapies.
• CRISPR Therapeutics is advancing a pipeline of allogeneic CAR-T cell therapies targeting various hematologic malignancies and solid tumors.
• The company is developing in vivo gene-editing programs targeting diseases of the liver, lung, muscle, and central nervous system.
• CRISPR Therapeutics has a strong intellectual property position in the CRISPR/Cas9 gene editing field.

Who Are CRSP's Competitors?

CRSP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRSP's Key Strengths?

• Proprietary CRISPR/Cas9 technology.
• Strong intellectual property position.
• Experienced management team.
• Strategic partnerships with leading healthcare companies.

What Are CRSP's Weaknesses?

• High research and development costs.
• Dependence on clinical trial outcomes.
• Regulatory hurdles.
• Negative profit and gross margins.

What Could Drive CRSP Stock Higher?

• Regulatory approval and commercial launch of CTX001 for beta-thalassemia and sickle cell disease.
• Clinical trial results from allogeneic CAR-T cell therapy programs.
• Progress in the development of in vivo gene-editing programs.
• New strategic partnerships and collaborations.

What Are the Key Risks for CRSP?

• Negative return on equity (-30.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Adverse clinical trial results.
• Regulatory delays or rejection of product approvals.
• Competition from other gene-editing companies.
• High research and development costs.
• Ethical concerns surrounding gene editing.

What Are the Growth Opportunities for CRSP?

• Growth opportunity 1: Commercialization of CTX001: The successful commercialization of CTX001 for beta-thalassemia and sickle cell disease represents a significant growth opportunity for CRISPR Therapeutics. These diseases affect a large patient population worldwide, and CTX001 has the potential to be a curative therapy. The market for beta-thalassemia and sickle cell disease treatments is estimated to be worth billions of dollars annually. CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, is preparing for regulatory submissions and commercial launch, which could drive substantial revenue growth.
• Growth opportunity 2: Expansion of Allogeneic CAR-T Cell Therapy Pipeline: CRISPR Therapeutics is advancing a pipeline of allogeneic CAR-T cell therapies targeting various hematologic malignancies and solid tumors. Allogeneic CAR-T therapies offer several advantages over autologous CAR-T therapies, including lower manufacturing costs and faster treatment times. The market for CAR-T cell therapies is projected to grow rapidly in the coming years, and CRISPR Therapeutics is well-positioned to capture a significant share of this market with its innovative allogeneic CAR-T platform.
• Growth opportunity 3: Development of In Vivo Gene-Editing Programs: CRISPR Therapeutics is developing in vivo gene-editing programs targeting diseases of the liver, lung, muscle, and central nervous system. In vivo gene editing involves delivering gene-editing machinery directly into the patient's body, which could potentially treat a wider range of diseases than ex vivo gene editing. The market for in vivo gene-editing therapies is still in its early stages, but it has the potential to be very large. CRISPR Therapeutics is investing heavily in its in vivo gene-editing platform and is expected to launch several clinical trials in the coming years.
• Growth opportunity 4: Strategic Partnerships and Collaborations: CRISPR Therapeutics has established strategic partnerships with leading healthcare companies, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. These partnerships provide CRISPR Therapeutics with access to additional resources, expertise, and funding to accelerate the development and commercialization of its gene-editing therapies. CRISPR Therapeutics is actively seeking new partnerships and collaborations to expand its pipeline and reach new markets.
• Growth opportunity 5: Expansion into New Therapeutic Areas: CRISPR Therapeutics is exploring the use of its CRISPR/Cas9 platform to develop therapies for a wider range of diseases, including autoimmune diseases, infectious diseases, and neurological disorders. The company is investing in research and development to identify new therapeutic targets and develop novel gene-editing strategies. Expansion into new therapeutic areas could significantly increase CRISPR Therapeutics' long-term growth potential.

What Opportunities Does CRSP Have?

• Commercialization of CTX001.
• Expansion of allogeneic CAR-T cell therapy pipeline.
• Development of in vivo gene-editing programs.
• Expansion into new therapeutic areas.

What Threats Does CRSP Face?

• Competition from other gene-editing companies.
• Adverse clinical trial results.
• Changes in regulatory landscape.
• Ethical concerns surrounding gene editing.

What Are CRSP's Competitive Advantages?

• Proprietary CRISPR/Cas9 gene-editing platform.
• Strong intellectual property portfolio.
• First-mover advantage in the gene-editing field.
• Strategic partnerships with leading healthcare companies.

What Does CRSP Do?

CRISPR Therapeutics AG, founded in 2013 and headquartered in Zug, Switzerland, is a pioneering gene editing company dedicated to developing transformative gene-based medicines for serious human diseases. The company's core technology revolves around the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform, a revolutionary gene editing tool that allows for precise and directed changes to genomic DNA. This technology holds immense potential for correcting genetic defects and developing curative therapies for a wide range of diseases. CRISPR Therapeutics has built a diverse portfolio of therapeutic programs spanning various disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Its lead product candidate, CTX001 (co-developed with Vertex Pharmaceuticals), is an ex vivo CRISPR gene-edited therapy designed to treat patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. CTX001 involves engineering a patient's hematopoietic stem cells to produce high levels of fetal hemoglobin in red blood cells, potentially eliminating the need for blood transfusions. Beyond CTX001, CRISPR Therapeutics is advancing a pipeline of allogeneic CAR-T cell therapies, including CTX110, CTX120, and CTX130, targeting various hematologic malignancies and solid tumors. The company is also developing VCTX210 for the treatment of type 1 diabetes, as well as in vivo gene-editing programs targeting diseases of the liver, lung, muscle, and central nervous system. CRISPR Therapeutics has established strategic partnerships with leading healthcare companies, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics, to accelerate the development and commercialization of its gene-editing therapies.

What Products and Services Does CRSP Offer?

• Develops gene-based medicines for serious diseases.
• Utilizes the CRISPR/Cas9 platform for precise gene editing.
• Focuses on ex vivo and in vivo gene-editing programs.
• Develops therapies for hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
• Engineers hematopoietic stem cells to produce fetal hemoglobin.
• Creates allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors.
• Targets diseases of the liver, lung, muscle, and central nervous system.

How Does CRSP Make Money?

• Develops and commercializes gene-editing therapies.
• Generates revenue through product sales and licensing agreements.
• Collaborates with pharmaceutical companies for research and development.
• Out-licenses its CRISPR/Cas9 technology for specific applications.

What Industry Does CRSP Operate In?

CRISPR Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the gene editing segment. The gene editing market is projected to experience substantial growth in the coming years, driven by advancements in gene editing technologies and the increasing prevalence of genetic diseases. CRISPR Therapeutics competes with other gene editing companies, such as ARWR: Arrowhead Pharmaceuticals, Inc. and KRYS: Krystal Biotech, Inc., as well as larger pharmaceutical companies that are investing in gene therapy. The company's CRISPR/Cas9 platform provides a competitive advantage, enabling precise and efficient gene editing. The industry is subject to stringent regulatory oversight, and companies must navigate complex clinical trial and approval processes.

Who Are CRSP's Key Customers?

• Patients suffering from genetic diseases.
• Hospitals and clinics that administer gene-editing therapies.
• Pharmaceutical companies that partner with CRISPR Therapeutics.
• Research institutions that use CRISPR/Cas9 technology.

Company Profile

CRISPR Therapeutics AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Zug, CH. The company is led by CEO Samarth Kulkarni. CRSP has traded publicly since 2016.

How CRISPR Therapeutics AG Is Valued

CRISPR Therapeutics AG carries a market capitalization of $5.96B, placing it in the mid-cap category. Relative to its peer group, CRSP's quantitative score of 44/100 is below the peer average of 62/100.

ROE -31%Key Financial Metrics

Return on equity for CRISPR Therapeutics AG stands at -30.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 17.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

CRISPR Therapeutics AG's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.09 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project CRISPR Therapeutics AG revenue of about $35.7M for fiscal 2026, with EPS near $-4.83. The estimate reflects 16 contributing analysts.

Net buyingInsider Activity

Over the past six months, CRISPR Therapeutics AG insiders filed 30 SEC Form 4 transactions — 7 sales and 23 purchases. On net that is roughly 500K shares acquired (about $14.6M) — insiders putting money in tends to read as conviction.

CRSP Financials

CRSP Latest News

CRSP Analyst Consensus

CRSP MoonshotScore

Latest CRISPR Therapeutics AG Analysis

Related Investment Themes

Common Questions About CRSP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources